Human tissue distribution of voriconazole

Antimicrobial Agents and Chemotherapy

Volumn 55, Issue 2, 2011, Pages 925-928

  Weiler, Stefan ^a   Fiegl, David ^a   MacFarland, Róisín ^a   Stienecke, Eva ^a   Bellmann Weiler, Rosa ^a   Dunzendorfer, Stefan ^a   Joannidis, Michael ^a   Bellmann, Romuald ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

VORICONAZOLE;

ADULT; AGED; ARTICLE; AUTOPSY; BRAIN; DRUG DISTRIBUTION; FEMALE; HEART MUSCLE; HUMAN; HUMAN TISSUE; KIDNEY; LIVER; LUNG; MALE; PRIORITY JOURNAL; SPLEEN;

ADULT; AGED; ASPERGILLOSIS; AUTOPSY; BRAIN; FEMALE; HUMANS; KIDNEY; LIVER; LUNG; MALE; MIDDLE AGED; MYOCARDIUM; PYRIMIDINES; SPLEEN; TISSUE DISTRIBUTION; TRIAZOLES; YOUNG ADULT;

EID: 78751680158     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00949-10     Document Type: Article

References (28)

1. Ballesta, S., I. Garcia, E. J. Perea, and A. Pascual. 2005. Uptake and intracellular activity of voriconazole in human polymorphonuclear leucocytes. J. Antimicrob. Chemother. 55:785-787.
2. Burhenne, J., W. E. Haefeli, M. Hess, and A. Scope. 2008. Pharmacokinetics, tissue concentrations, and safety of the antifungal agent voriconazole in chickens. J. Avian Med. Surg. 22:199-207.
3. Capitano, B., et al. 2006. Intrapulmonary penetration of voriconazole in patients receiving an oral prophylactic regimen. Antimicrob. Agents Chemother. 50:1878-1880.
4. Colitz, C. M., et al. 2007. Pharmacokinetics of voriconazole following intravenous and oral administration and body fluid concentrations of voriconazole following repeated oral administration in horses. Am. J. Vet. Res. 68:1115-1121.
5. Crandon, J. L., et al. 2009. Bronchopulmonary disposition of intravenous voriconazole and anidulafungin given in combination to healthy adults. Antimicrob. Agents Chemother. 53:5102-5107.
6. Denes, E., N. Pichon, M. Debette-Gratien, B. Bouteille, and J. M. Gaulier. 2004. Pharmacokinetics of voriconazole in the cerebrospinal fluid of an immunocompromised patient with a brain abscess due to Aspergillus fumigatus. Clin. Infect. Dis. 39:603-604.
7. De Pauw, B., et al. 2008. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin. Infect. Dis. 46:1813-1821.
8. Elter, T., et al. 2006. Voriconazole brain tissue levels in rhinocerebral aspergillosis in a successfully treated young woman. Int. J. Antimicrob. Agents 28:262-265.
9. Groll, A. H., et al. 2001. Pharmacokinetic and pharmacodynamic modeling of anidulafungin (LY303366): reappraisal of its efficacy in neutropenic animal models of opportunistic mycoses using optimal plasma sampling. Antimicrob. Agents Chemother. 45:2845-2855.
10. Groll, A. H., et al. 2001. Compartmental pharmacokinetics and tissue distribution of the antifungal echinocandin lipopeptide micafungin (FK463) in rabbits. Antimicrob. Agents Chemother. 45:3322-3327.
11. Han, K., et al. 2010. Bioavailability and population pharmacokinetics of voriconazole in lung transplant recipients. Antimicrob. Agents Chemother. 54:4424-4431.
12. Herbrecht, R., et al. 2002. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N. Engl. J. Med. 347:408-415.
13. Joukhadar, C., et al. 2009. Concentrations of voriconazole in healthy and inflamed lung in rats. Antimicrob. Agents Chemother. 53:2684-2686.
14. Khoschsorur, G., F. Fruehwirth, and S. Zelzer. 2005. Isocratic high-performance liquid chromatographic method with ultraviolet detection for simultaneous determination of levels of voriconazole and itraconazole and its hydroxy metabolite in human serum. Antimicrob. Agents Chemother. 49:3569-3571.
15. Lass-Florl, C., et al. 2008. Activities of antifungal agents against yeasts and filamentous fungi: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing. Antimicrob. Agents Chemother. 52:3637-3641.
16. Lutsar, I., S. Roffey, and P. Troke. 2003. Voriconazole concentrations in the cerebrospinal fluid and brain tissue of guinea pigs and immunocompromised patients. Clin. Infect. Dis. 37:728-732.
17. Matsuda, T., et al. 2010. A case of Aspergillus empyema successfully treated with combination therapy of voriconazole and micafungin: excellent penetration of voriconazole and micafungin into pleural fluid. Intern. Med. 49:1163-1169.
18. Müller, M., A. dela Peña, and H. Derendorf. 2004. Issues in pharmacokinetics and pharmacodynamics of anti-infective agents: distribution in tissue. Antimicrob. Agents Chemother. 48:1441-1453.
19. Pascual, A., et al. 2008. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Clin. Infect. Dis. 46:201-211.
20. Passler, N. H., et al. 2010. Distribution of voriconazole in seven body fluids of adult horses after repeated oral dosing. J. Vet. Pharmacol. Ther. 33:35-41.
21. Poupelin, J. C., et al. 2006. Pericardial and pleural diffusion of voriconazole during disseminated invasive aspergillosis: report of a case with successful outcome. Intensive Care Med. 32:939-940.
22. Smith, J., et al. 2006. Voriconazole therapeutic drug monitoring. Antimicrob. Agents Chemother. 50:1570-1572.
23. Stern, J. B., P. Girard, and R. Caliandro. 2004. Pleural diffusion of voriconazole in a patient with Aspergillus fumigatus empyema thoracis. Antimicrob. Agents Chemother. 48:1065.
24. Stone, J. A., et al. 2004. Disposition of caspofungin: role of distribution in determining pharmacokinetics in plasma. Antimicrob. Agents Chemother. 48:815-823.
25. Thaler, F., et al. 1995. Fluconazole penetration in cerebral parenchyma in humans at steady state. Antimicrob. Agents Chemother. 39:1154-1156.
26. Vogelsinger, H., et al. 2006. Amphotericin B tissue distribution in autopsy material after treatment with liposomal amphotericin B and amphotericin B colloidal dispersion. J. Antimicrob. Chemother. 57:1153-1160.
27. Walsh, T. J., et al. 2008. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin. Infect. Dis. 46:327-360.
28. Weiler, S., et al. 2009. Pulmonary epithelial lining fluid concentrations after use of systemic amphotericin B lipid formulations. Antimicrob. Agents Chemother. 53:4934-4937.